JP6532404B2 - 細胞株 - Google Patents

細胞株 Download PDF

Info

Publication number
JP6532404B2
JP6532404B2 JP2015532457A JP2015532457A JP6532404B2 JP 6532404 B2 JP6532404 B2 JP 6532404B2 JP 2015532457 A JP2015532457 A JP 2015532457A JP 2015532457 A JP2015532457 A JP 2015532457A JP 6532404 B2 JP6532404 B2 JP 6532404B2
Authority
JP
Japan
Prior art keywords
pylrs
cell line
cells
trnapyl
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015532457A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530091A (ja
Inventor
エイチ． グラブステイン，ケネス
エイチ． グラブステイン，ケネス
ブラント，マイケル ヴァン
ブラント，マイケル ヴァン
マレッリ，マルチェッロ
ブラディー，ウィリアム
ジョンソン，ジェフリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of JP2015530091A publication Critical patent/JP2015530091A/ja
Application granted granted Critical
Publication of JP6532404B2 publication Critical patent/JP6532404B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/49—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C247/00—Compounds containing azido groups
    • C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01025—1,4-Lactonase (3.1.1.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y601/00—Ligases forming carbon-oxygen bonds (6.1)
    • C12Y601/01—Ligases forming aminoacyl-tRNA and related compounds (6.1.1)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015532457A 2012-09-24 2013-09-24 細胞株 Active JP6532404B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261705116P 2012-09-24 2012-09-24
US61/705,116 2012-09-24
US201361862495P 2013-08-05 2013-08-05
US61/862,495 2013-08-05
PCT/EP2013/069887 WO2014044872A1 (en) 2012-09-24 2013-09-24 Cell lines

Publications (2)

Publication Number Publication Date
JP2015530091A JP2015530091A (ja) 2015-10-15
JP6532404B2 true JP6532404B2 (ja) 2019-06-19

Family

ID=49237211

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015532457A Active JP6532404B2 (ja) 2012-09-24 2013-09-24 細胞株
JP2015532458A Expired - Fee Related JP6321658B2 (ja) 2012-09-24 2013-09-24 アミノ酸誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015532458A Expired - Fee Related JP6321658B2 (ja) 2012-09-24 2013-09-24 アミノ酸誘導体

Country Status (10)

Country Link
US (4) US9670521B2 (enExample)
EP (2) EP2897935B1 (enExample)
JP (2) JP6532404B2 (enExample)
KR (1) KR102155389B1 (enExample)
CN (2) CN104812734B (enExample)
AU (1) AU2013320184B2 (enExample)
BR (1) BR112015006368B1 (enExample)
CA (1) CA2885796C (enExample)
SG (2) SG11201502216UA (enExample)
WO (2) WO2014044873A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2825370A1 (en) 2010-12-22 2012-06-28 President And Fellows Of Harvard College Continuous directed evolution
JP6343604B2 (ja) 2012-05-18 2018-06-13 メディカル リサーチ カウンシル ＢＣＮ基を含むアミノ酸をコードする直交性コドンと、直交性ＰｙｌＲＳ合成酵素とを使用して、ＢＣＮ基を含むアミノ酸をポリペプチドに取り込む方法
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
EP2863955B1 (en) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
BR112015006368B1 (pt) 2012-09-24 2022-02-08 Medimmune Limited Processo para produção de linha celular eucariótica estável
CA2906292C (en) 2013-03-15 2022-08-02 Medimmune Limited Novel dna constructs for the expression of trnapyl genes in eukaryotic cells
WO2015006555A2 (en) * 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3030545B1 (en) 2013-08-05 2020-10-07 MedImmune Limited Amino acid derivatives
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
EP3097196B1 (en) 2014-01-20 2019-09-11 President and Fellows of Harvard College Negative selection and stringency modulation in continuous evolution systems
GB2528227A (en) * 2014-03-14 2016-01-20 Medical Res Council Cyclopropene amino acids and methods
WO2016077052A2 (en) 2014-10-22 2016-05-19 President And Fellows Of Harvard College Evolution of proteases
KR102754019B1 (ko) 2014-10-29 2025-01-14 바이시클러드 리미티드 Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
CN106146663B (zh) * 2015-04-10 2019-11-08 北京大学 非天然氨基酸标记的新型抗体-药物偶联物及其制备
US11299729B2 (en) 2015-04-17 2022-04-12 President And Fellows Of Harvard College Vector-based mutagenesis system
WO2017015545A1 (en) 2015-07-22 2017-01-26 President And Fellows Of Harvard College Evolution of site-specific recombinases
WO2017015559A2 (en) 2015-07-23 2017-01-26 President And Fellows Of Harvard College Evolution of bt toxins
WO2017019895A1 (en) 2015-07-30 2017-02-02 President And Fellows Of Harvard College Evolution of talens
JP6967221B2 (ja) * 2015-08-19 2021-11-17 国立研究開発法人理化学研究所 非天然アミノ酸導入抗体
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
CN106929482A (zh) * 2015-12-31 2017-07-07 北京大学 定点突变的流感病毒、其活疫苗及其制备方法和应用
MX2018009085A (es) 2016-01-27 2019-05-09 Sutro Biopharma Inc Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
CN107012121B (zh) * 2016-01-27 2021-01-26 北京大学 携带正交tRNA/氨酰tRNA合成酶的稳定细胞系的构建
CN105524167A (zh) * 2016-01-30 2016-04-27 深圳市贝沃德克生物技术研究院有限公司 抗乙肝e抗原的绿色荧光抗体的制备方法
CN105647918A (zh) * 2016-02-20 2016-06-08 深圳市圣必智科技开发有限公司 抗乙肝e抗原的红色荧光抗体的制备方法
MX2018015684A (es) 2016-06-17 2019-08-29 Magenta Therapeutics Inc Composiciones y metodos para el agotamiento de celulas cd117.
US11214820B2 (en) * 2016-09-02 2022-01-04 Ikaria Inc. Functionally modified polypeptides and radiobiosynthesis
US10905107B2 (en) * 2016-09-05 2021-02-02 Korea Advanced Institute Of Science And Technology Transgenic mouse capable of spatial and temporal control of expression and site-specific modification of target protein, production method and uses thereof
WO2018044143A1 (ko) * 2016-09-05 2018-03-08 한국과학기술원 목적 단백질의 위치 특이적 변형이 시공간적으로 조절되는 마우스, 이의 제조방법 및 그 용도
US11730819B2 (en) 2016-12-23 2023-08-22 Bicycletx Limited Peptide derivatives having novel linkage structures
IL268058B2 (en) 2017-01-20 2023-09-01 Magenta Therapeutics Inc Compositions and methods for depleting cd137 plus cells
CN111032678A (zh) 2017-06-26 2020-04-17 拜西克尔德有限公司 具有可检测部分的双环肽配体和其用途
WO2019010164A1 (en) * 2017-07-06 2019-01-10 President And Fellows Of Harvard College Evolution of trna synthetases
ES2926195T3 (es) 2017-08-04 2022-10-24 Bicycletx Ltd Ligandos peptídicos bicíclicos específicos de CD137
WO2019040935A1 (en) 2017-08-25 2019-02-28 President And Fellows Of Harvard College EVOLUTION OF PEPTIDASES BONT
WO2019056002A1 (en) 2017-09-18 2019-03-21 President And Fellows Of Harvard College CONTINUOUS EVOLUTION FOR STABILIZED PROTEINS
JP7275049B2 (ja) 2017-12-27 2023-05-17 協和キリン株式会社 Ｉｌ－２改変体
AU2019224659A1 (en) 2018-02-23 2020-10-15 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2019241649A1 (en) 2018-06-14 2019-12-19 President And Fellows Of Harvard College Evolution of cytidine deaminases
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CN110835633B (zh) * 2018-08-13 2021-10-01 北京大学 利用优化的基因密码子扩展系统制备ptc稳定细胞系及应用
CN112673109A (zh) * 2018-09-07 2021-04-16 免疫医疗有限责任公司 细胞选择方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
GB201817444D0 (en) 2018-10-26 2018-12-12 Res & Innovation Uk Methods and compositions
CN109553643B (zh) * 2018-11-29 2020-09-22 深圳先进技术研究院 单糖类似物及包含其的分子探针和该分子探针的应用
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
US12551567B2 (en) 2018-12-21 2026-02-17 Bicyclerd Limited Bicyclic peptide ligands specific for PD-L1
CN113474045A (zh) 2018-12-21 2021-10-01 拜斯科技术开发有限公司 Pd-l1特异性的双环肽配体
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
CN111850020B (zh) * 2019-04-25 2021-05-07 苏州鲲鹏生物技术有限公司 利用质粒系统在蛋白中引入非天然氨基酸
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CA3155908A1 (en) * 2019-10-23 2021-04-29 University Of Florida Research Foundation, Incorporated Novel conjugation chemistry for catalytic antibody 38c2
CA3189761A1 (en) 2020-08-03 2022-02-10 Gemma Mudd Peptide-based linkers
WO2022056318A1 (en) * 2020-09-10 2022-03-17 Brickbio, Inc. Antibodies containing unnatural amino acids and methods of making and using the same
MX2023012518A (es) * 2021-04-21 2024-02-08 Asimov Inc Sistemas de producción estables para la producción de virus adenoasociado.
WO2022232377A2 (en) * 2021-04-28 2022-11-03 The Regents Of The University Of California Bioreactive proteins containing unnatural amino acids
AU2021458069B2 (en) * 2021-07-29 2025-04-24 Novocodex Biopharmaceuticals Co., Ltd. Unnatural amino acid, and use thereof, recombinant protein containing same, and recombinant protein conjugate
EP4130254A1 (en) * 2021-08-03 2023-02-08 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Eukaryotic cell lysates comprising exogenous enzymes and methods for preparing the same
CN113698468B (zh) * 2021-09-01 2022-10-11 浙江新码生物医药有限公司 人白细胞介素2-聚乙二醇偶联物及其应用
CN113788890B (zh) * 2021-09-01 2022-11-08 浙江新码生物医药有限公司 一种人白细胞介素2-聚乙二醇偶联物及其应用
WO2023164676A1 (en) * 2022-02-27 2023-08-31 The Regents Of The University Of California Methods to generate novel acyl-trna species
US20260070874A1 (en) * 2023-04-05 2026-03-12 Kj Chemicals Corporation Benzoylformic acid amide derivative
WO2024223923A1 (en) * 2023-04-28 2024-10-31 United Kingdom Research And Innovation tRNA-BASED METHODS AND RELATED COMPOSITIONS
WO2025011557A1 (en) * 2023-07-10 2025-01-16 Surio Therapeutics Co. Ltd Functionalized auristatins, pharmaceutical compositions, and therapeutic applications

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711458A (en) 1969-08-21 1973-01-16 Research Corp Substituted and unsubstituted vinyloxycarbonyl groups as amino protecting groups in the syntheses of peptides
US4512979A (en) 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
JPH0710451B2 (ja) 1986-11-25 1995-02-08 三五重機株式会社 鋼板カツタ−
HU207287B (en) 1989-01-17 1993-03-29 Biosignal Kutato Fejlesztoe Kf Polyene fatty acid derivatives of tyrozine-quinaze inhibiting activity and pharmaceutical composition containing them as active component
WO1991016449A1 (en) 1990-04-16 1991-10-31 The Trustees Of The University Of Pennsylvania Saccharide compositions, methods and apparatus for their synthesis
IL158418A0 (en) 2001-04-19 2004-05-12 Scripps Research Inst In vivo incorporation of unnatural amino acids
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
MXPA05003978A (es) 2002-10-16 2005-06-22 Scripps Research Inst Sintesis de glicoproteinas.
US20040146941A1 (en) * 2002-11-04 2004-07-29 Biliang Zhang Chemical encoding technology for combinatorial synthesis
CN103289960B (zh) * 2003-04-17 2017-04-26 斯克利普斯研究院 扩展真核生物遗传密码
EP1812031B1 (en) 2004-11-01 2015-06-24 The Regents of the University of California Compositions and methods for modification of biomolecules
JP2007037445A (ja) 2005-08-02 2007-02-15 Institute Of Physical & Chemical Research ｔＲＮＡ合成方法、核酸、アミノアシルｔＲＮＡ合成方法及び非天然型アミノ酸組み込み蛋白質の製造方法
EP1992698B1 (en) 2006-02-22 2018-09-05 Riken METHOD FOR SYNTHESIS OF SUPPRESSOR tRNA, DNA CONSTRUCT, AND PRODUCTION OF PROTEIN HAVING NON-NATURAL AMINO ACID INTEGRATED THEREIN BY USING THE DNA CONSTRUCT
EP2581450B1 (en) 2006-05-02 2018-08-15 MedImmune Limited Non-natural amino acid substituted polypeptides
KR20090094812A (ko) * 2006-10-18 2009-09-08 더 스크립스 리서치 인스티튜트 포유동물 세포에서 비천연 아미노산의 단백질 내로의 유전적 도입
JP5590649B2 (ja) 2007-09-20 2014-09-17 独立行政法人理化学研究所 変異体ピロリジル−ｔＲＮＡ合成酵素及びこれを用いる非天然アミノ酸組み込みタンパク質の製造方法
JP2011528416A (ja) 2008-07-18 2011-11-17 アラントゥーム 自動車の排気ガス浄化用フィルタ装置
EP2376647B1 (en) 2009-01-12 2014-03-05 Sutro Biopharma, Inc. Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system
US20100203587A1 (en) 2009-01-13 2010-08-12 Sutro Biopharma, Inc. Use of dna gyrase inhibitors for in vitro polypeptide synthesis reactions
WO2010114615A2 (en) 2009-04-03 2010-10-07 The Scripps Research Institute A facile system for encoding unnatural amino acids in mammalian cells
GB2470770A (en) 2009-06-04 2010-12-08 Medical Res Council Incorporation of unnatural amino acids having an orthogonal functional group into polypeptides using orthogonal tRNA/tRNA synthetase pairs
US8921571B2 (en) * 2009-10-06 2014-12-30 The Ohio State University Pyrrolysine analogs
NZ600361A (en) * 2009-12-21 2014-06-27 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EP2516455A4 (en) * 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
EP2894142B1 (en) 2010-04-27 2019-06-12 SynAffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
DE102010041261A1 (de) * 2010-09-23 2012-03-29 Robert Bosch Gmbh Flip-Chip Anordnung mit einem Kühlelement und Verfahren zur Herstellung einer Flip-Chip Anordnung
EP2619305A1 (en) * 2010-09-24 2013-07-31 Medical Research Council Methods for incorporating unnatural amino acids in eukaryotic cells
EP3279211B1 (en) * 2011-02-03 2020-04-29 Embl Unnatural amino acids comprising a norbornenyl group and uses thereof
DK2890402T3 (da) 2012-08-31 2019-07-15 Sutro Biopharma Inc Modificerede aminosyrer omfattende en azidogruppe
BR112015006368B1 (pt) 2012-09-24 2022-02-08 Medimmune Limited Processo para produção de linha celular eucariótica estável
CA2906292C (en) 2013-03-15 2022-08-02 Medimmune Limited Novel dna constructs for the expression of trnapyl genes in eukaryotic cells

Also Published As

Publication number Publication date
CN104812734A (zh) 2015-07-29
WO2014044873A1 (en) 2014-03-27
CA2885796A1 (en) 2014-03-27
EP2897935B1 (en) 2019-02-27
US10253345B2 (en) 2019-04-09
EP2898085A1 (en) 2015-07-29
US10214761B2 (en) 2019-02-26
WO2014044872A1 (en) 2014-03-27
CN105026574A (zh) 2015-11-04
US20150251994A1 (en) 2015-09-10
US20150259721A1 (en) 2015-09-17
AU2013320184A1 (en) 2015-04-09
EP2897935A1 (en) 2015-07-29
CN105026574B (zh) 2019-08-30
SG10201702387YA (en) 2017-04-27
AU2013320184B2 (en) 2017-10-12
HK1211623A1 (en) 2016-05-27
JP2015530091A (ja) 2015-10-15
BR112015006368B1 (pt) 2022-02-08
BR112015006368A2 (enExample) 2017-09-05
EP2898085B1 (en) 2019-01-23
US9670521B2 (en) 2017-06-06
KR20150070186A (ko) 2015-06-24
CN104812734B (zh) 2017-08-22
SG11201502216UA (en) 2015-04-29
JP6321658B2 (ja) 2018-05-09
US20170306380A1 (en) 2017-10-26
KR102155389B1 (ko) 2020-09-11
HK1211569A1 (en) 2016-05-27
US9732367B2 (en) 2017-08-15
CA2885796C (en) 2022-05-03
JP2015531789A (ja) 2015-11-05
US20170306381A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CA2885796C (en) Cell lines
US20250161479A1 (en) Transglutaminase conjugation method and linker
US9981908B2 (en) Amino acid derivatives
JP2024510435A (ja) 生体活性化合物の内部移行複合体からの選択的薬物放出
HK1211623B (en) Cell lines
KR20260046379A (ko) 유기 세포독소 올리고머 및 항체-약물 접합체에서의 페이로드로서의 그의 용도
JP2025528452A (ja) 抗体薬物コンジュゲートのペイロードとして使用するための有機細胞毒素を修飾する方法およびそれらから誘導される修飾有機細胞毒素
HK1211569B (en) Amino acid derivatives
HK1225372B (en) Amino acid derivatives

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150723

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150723

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150724

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170822

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190521

R150 Certificate of patent or registration of utility model

Ref document number: 6532404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250